About the Program
Calendar 2018
Calendar 2017
Calendar 2016
Calendar 2015
Calendar 2014
Calendar 2013
Calendar 2012
Calendar 2011
The Students
Class of 2017
Class of 2016
Class of 2015
Class of 2014
Class of 2013
Class of 2012
Class of 2011
Class of 2010
Class of 2009
Class of 2008
Class of 2007
Class of 2006
Class of 2005
Class of 2004
Class of 2003
Class of 2002
Class of 2001
Class of 2000
Class of 1999
Class of 1997
Class of 1996
Research and Faculty
Coordinating Committee
Module Coordinators
PhD Degrees Completed
Events and Highlights
All Time GABBAs
Reserved Area
Forgot your password?
Class of 1996
Macedo, Fátima
Master Degree
About the PhD
Field of Research
Thesis Title
CD8+ T cell subpopulations in Hereditary Hemochromatosis
Maria de Sousa; Graça Porto
Porto University
Loyola University, Chicago; MGH, Children s Hospital, Harvard University Boston; IBMC Porto
Date of Thesis Defence

Relevant Publications
Macedo MF, de Sousa M.
Transferrin and the transferrin receptor: of magic bullets and other concerns.
Inflamm Allergy Drug Targets. 2008;7:41-52.
Macedo MF, Cruz E, Lacerda R, Porto G, de Sousa M.
Low serum transferrin levels in HFE C282Y homozygous subjects are associated with low CD8(+) T lymphocyte numbers.
Blood Cells Mol Dis. 2005;35:319-25
Macedo MF, de Sousa M, Ned RM, Mascarenhas C, Andrews NC, Correia-Neves M.
Transferrin is required for early T-cell differentiation.
Immunology. 2004;112:543-9.
Velders MP, Macedo MF, Provenzano M, Elmishad AG, Holzhütter HG, Carbone M,
Kast WM.
Human T cell responses to endogenously presented HLA-A*0201 restricted peptides of Simian virus 40 large T antigen.
J Cell Biochem. 2001 2-27;82:155-62.

Macedo MF, Velders MP, Nieland JD, Rudolf MP, Weijzen S, Da Silva DM, Franke
A, Holt G, Loviscek K, Carbone M, Kast WM.
Cellular immunity and immunotherapy against deoxyribonucleic acid virus-induced tumors.
Monaldi Arch Chest Dis. 1998 ;53:211-8.
Velders MP, Nieland JD, Rudolf MP, Loviscek K, Weijzen S, de Visser KE, Macedo
MF, Carbone M, Kast WM.
Identification of peptides for immunotherapy of cancer. It is worth the effort.
Crit Rev Immunol. 1998;18:7-27.

The responsibility for this page contents is entirely of the student/alumnus.
Program financially supported by
the National Foundation for
Science and Technology